Urology · Overactive BladderSafety Signalregulatorymid-term

Quadrant Pharmaceuticals Issues Class 4 Medicines Defect Notification for Vesomni Tablets

The Class 4 Medicines Defect Notification for Vesomni tablets indicates a significant regulatory issue that could disrupt distribution and patient access. This situation necessitates close monitoring to assess its impact on market dynamics and compliance requirements.

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 12:35:14 AM

Assessment confidence: 49% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

Strategic Assessment

Portfolio teams should assess the potential impact on sales and consider strategies to mitigate supply chain disruptions. The strongest clinical anchor is Device for Bladder Control for Men With SCI (ClinicalTrials.gov), moderate corpus alignment. In Urology · Overactive Bladder, 5 regulatory and 5 competitive items passed relevance filtering for Quadrant Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (Lilly) — sponsor/company relevance (lilly). Secondary pressure from Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments. This defect may impact the distribution and availability of Vesomni, potentially affecting market share and patient access.

Regulatory Outlook

Regulatory risk is concentrated around Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28 (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. The incorrect barcode/GTIN could lead to compliance issues with the MHRA, necessitating corrective actions that may delay product availability.

Key Risks

Elevated medium regulatory exposure for Quadrant Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Impact of Cesarean Scar Defects on the Success of Assisted Human Reproduction) could weigh on Quadrant Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The defect may lead to reduced market share for Vesomni if distribution is affected, potentially impacting revenue streams for Quadrant Pharmaceuticals.
Upside for Quadrant Pharmaceuticals may improve if Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review. (PubMed) delivers favorable follow-through.
Upside for Quadrant Pharmaceuticals may improve if Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial (ClinicalTrials.gov) delivers favorable follow-through.
Various · Pharmaceuticals · Safety Signal · This recall may impact Bayer's market share and consumer trust, potentially benefiting competitors with similar products.
Neurology · Sleep Disorders · Safety Signal · This recall may impact market confidence in KidNaps and similar melatonin products, potentially benefiting competitors with stable formulations.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the resolution of the defect and any regulatory actions taken by the MHRA.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA notification regarding unapproved drugs included in kits
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Notice: Register of authorised online sellers of medicines in Northern Ireland
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Device for Bladder Control for Men With SCI
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Impact of Cesarean Scar Defects on the Success of Assisted Human Reproduction
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Human Experimental Models of Pain (HEMP)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lillyhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
Humanexa Signalsmedium relevance
Sponsor/company relevance (Lilly)
Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sterling Pharmaceuticals recalls KidNaps Melatonin due to stability issues
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
Humanexa Signalsmedium relevance
Moderate corpus alignment

Systemic challenges in the supply and distribution of medicines in conflict-affected areas of Mali: a qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
AI-assisted case-based learning and flipped classroom to improve clinical decision-making: a randomized controlled trial in reproductive medicine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
m6A methylation of circKPNA2 promotes colorectal carcinogenesis by activating the RIN1-Ras pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Quadrant Pharmaceuticals
Vesomni

Commercial impact

medium

The defect may lead to reduced market share for Vesomni if distribution is affected, potentially impacting revenue streams for Quadrant Pharmaceuticals.

Regulatory impact

medium

The incorrect barcode/GTIN could lead to compliance issues with the MHRA, necessitating corrective actions that may delay product availability.

What to watch

Monitor for updates on the resolution of the defect and any regulatory actions taken by the MHRA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.